OncoMatch

OncoMatch/Clinical Trials/NCT06774131

A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer

Is NCT06774131 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies UGN-104 for upper urinary tract urothelial carcinoma.

Phase 3RecruitingUroGen Pharma Ltd.NCT06774131Data as of May 2026

Treatment: UGN-104This study will evaluate the efficacy and safety of UGN-104, a new formulation of UGN-101 (approved in the United States and Israel as JELMYTO \[mitomycin\] for pyelocalyceal solution), instilled in the upper urinary tract (UUT) of patients with low-grade upper tract urothelial cancer (LG-UTUC).

Check if I qualify

Extracted eligibility criteria

Cancer type

Urothelial Carcinoma

Disease stage

Grade: low-grade

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Cannot have received: Bacillus Calmette-Guérin

Patient received Bacillus Calmette-Guérin (BCG) treatment for UC during the 6 months before enrollment

Cannot have received: JELMYTO (UGN-101)

Patient was previously treated with JELMYTO (product code UGN-101) for UTUC

Lab requirements

Blood counts

Leukocytes ≥ 3,000/μL; ANC ≥ 1,500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 9.0 g/dL

Kidney function

eGFR ≥ 30 mL/min

Liver function

Total bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN

Patients must have adequate organ and bone marrow function as determined by the following routine laboratory tests: Leukocytes ≥ 3,000/μL; ANC ≥ 1,500/μL; Platelets ≥ 100,000/μL; Hemoglobin ≥ 9.0 g/dL; Total bilirubin ≤ 1.5 × ULN; AST and ALT ≤ 2.5 × ULN; Alkaline phosphatase ≤ 2.5 × ULN; eGFR ≥ 30 mL/min.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Urology Centers of Alabama · Homewood, Alabama
  • Arizona State Urological Research Institute, LLC ("ASURI") · Chandler, Arizona
  • Michael G Oefelein Clinical Trials · Bakersfield, California
  • University of California, Irvine · Orange, California
  • BioResearch Partners Aventura · Aventura, Florida

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify